Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors

Gene Therapy

Volumn 7, Issue 13, 2000, Pages 1087-1093

  Martino, G ^a   Poliani, P L ^a   Marconi, P C ^b   Comi, G ^a   Furlan, R ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Cytokines; EAE; Gene therapy; Herpetic vectors; Inflammation; MS

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; ENCEPHALITOGENIC PROTEIN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 4; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; DEMYELINATION; DRUG DELIVERY SYSTEM; EFFECTOR CELL; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; IMMUNOMODULATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0033910687     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301215     Document Type: Article

References (41)

1. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc Natl Acad Sci USA 1996; 93: 2253-2256.
2. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999; 12: 309-321.
3. Kieseier B et al. Effector pathways in immune mediated central nervous system demyelination. Curr Opin Neurol 1999; 12: 323-336.
4. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
5. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
6. Panitch NL, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-895.
7. Panitch NL, Hirsch RL, Schindler J, Johnson KP. Treatment of MS with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-1102.
8. Selmaj KW, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87: 949-954.
9. Beck J et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78: 318-323.
10. Calabresi PA, Tranquill LR, McFarland HF, Cowan EP. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J Neuroimmunol 1998; 89: 198-205.
11. Martino G et al. Proinflammatory cytokines regulate antigen-independent T cell activation by two separate calcium signaling pathways in multiple sclerosis patients. Ann Neurol 1998; 43: 340-349.
12. Correale J et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995; 154: 2959-2968.
13. Sørensen TL et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis. J Clin Invest 1999; 103: 6807-6815.
14. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45 (Suppl. 6): S11-S15.
15. Furlan R et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999; 163: 2403-2409.
16. Meinl E et al. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 1997; 150: 445-453.
17. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
18. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA, The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15.
19. Calabresi PA et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998; 51: 289-292.
20. The Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.
21. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I. Adult brain. Clin Exp Pharmacol Physiol 1999; 26: 11-19.
22. Khan OA et al. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996; 46: 1639-1643.
23. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
24. Shaw MK et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 1711-1174.
25. Dal Canto RA et al. Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Clin Immunol 1999; 90: 10-14.
26. Chen LZ et al. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-betal. Proc Natl Acad Sci USA 1998; 95: 12516-12521.
27. Mathisen PM et al. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997; 186: 159-164.
28. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines vising a recombinant vaccinia virus system. Scand J Immunol 1995; 41: 31-40.
29. Croxford JL et al. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1997; 160: 5181-5187.
30. Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y. Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Therapy 1998; 5: 253-263.
31. Piccirillo CA, Prud'homme GJ. Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum Gene Ther 1999; 10: 1915-1922.
32. Boccaccio GL, Mor F, Steinman L. Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. Intern Immunol 1999; 11: 289-296.
33. Tsunoda I et al. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol 1999; 9: 481-493.
34. Glorioso JC et al. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994; 35: S28-34.
35. Krisky DM et al. Rapid method for construction of recombinant HSV-1 gene transfer vectors. Gene Therapy 1997; 4: 1120-1125.
36. Marconi P et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320.
37. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
38. Kuklin NA et al. Modulation of mucosal and systemic immunity by enteric administration of non-replicating herpes simplex virus expressing cytokines. Virology 1998; 240: 245-253.
39. Martino G et al. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult Scler 1998; 4: 222-227.
40. Furlan R et al. Central nervous system delivery of interleukin-4 by a non-replicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 1998; 9: 2605-2617.
41. Furlan R et al. Interleukin-4 gene delivery in the central nervous inhibits ongoing experimental autoimmune encephalomyelitis (submitted for publication).